Long-term follow-up of posterior capsule opacification after AquaLase and NeoSoniX phacoemulsification

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F16%3A10316843" target="_blank" >RIV/00179906:_____/16:10316843 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/16:10316843

Výsledek na webu

<a href="http://dx.doi.org/10.5507/bp.2015.039" target="_blank" >http://dx.doi.org/10.5507/bp.2015.039</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2015.039" target="_blank" >10.5507/bp.2015.039</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Long-term follow-up of posterior capsule opacification after AquaLase and NeoSoniX phacoemulsification

Popis výsledku v původním jazyce

Aim. To compare the degree of posterior capsule opacification (PCO) after AquaLase and NeoSoniX phacoemulsification methods during an 8-year follow-up period using two types of software. Design. Prospective, randomized clinical trial. Methods. AquaLase was used in the right eye and NeoSoniX in the left eye of each patient with bilateral cataract. Results. Fifty patients were analyzed 1 year, 46 patients 3 years, and 37 patients 8 years after cataract surgery. Mean EPCO 2000 values were for the AquaLase group 0.324 +- 0.305 and for the NeoSoniX group 0.298 +- 0.341 (P = 0.53) 1 year after surgery, for the AquaLase group 0.582 +- 0.506 and for the NeoSoniX group 0.594 +- 0.515 (P = 0.87) 3 years after surgery, and for the AquaLase group 0.648 +- 0.567 and for the NeoSoniX group 0.673 +- 0.542 (P = 0.30) 8 years after surgery. The OSCA results were for the AquaLase group 0.7097 +- 0.3778 and for the NeoSoniX group 0.8584 +- 0.4323 (P = 0.046) 1 year after surgery, for the AquaLase group 0.9667 +- 0.736 and for the NeoSoniX group 0.9540 +- 0.5250 (P = 0.91) 3 years after surgery, and for the AquaLase group 1,035 +- 0,952 and for the NeoSoniX group 1,103 +- 0,741 (P = 0.44) 8 years after surgery. Conclusion. There was minimal PCO difference between these 2 approaches, AquaLase and NeoSoniX. Neither AquaLase nor NeoSoniX technique was able to prevent a natural progression of PCO.

Název v anglickém jazyce

Long-term follow-up of posterior capsule opacification after AquaLase and NeoSoniX phacoemulsification

Popis výsledku anglicky

Aim. To compare the degree of posterior capsule opacification (PCO) after AquaLase and NeoSoniX phacoemulsification methods during an 8-year follow-up period using two types of software. Design. Prospective, randomized clinical trial. Methods. AquaLase was used in the right eye and NeoSoniX in the left eye of each patient with bilateral cataract. Results. Fifty patients were analyzed 1 year, 46 patients 3 years, and 37 patients 8 years after cataract surgery. Mean EPCO 2000 values were for the AquaLase group 0.324 +- 0.305 and for the NeoSoniX group 0.298 +- 0.341 (P = 0.53) 1 year after surgery, for the AquaLase group 0.582 +- 0.506 and for the NeoSoniX group 0.594 +- 0.515 (P = 0.87) 3 years after surgery, and for the AquaLase group 0.648 +- 0.567 and for the NeoSoniX group 0.673 +- 0.542 (P = 0.30) 8 years after surgery. The OSCA results were for the AquaLase group 0.7097 +- 0.3778 and for the NeoSoniX group 0.8584 +- 0.4323 (P = 0.046) 1 year after surgery, for the AquaLase group 0.9667 +- 0.736 and for the NeoSoniX group 0.9540 +- 0.5250 (P = 0.91) 3 years after surgery, and for the AquaLase group 1,035 +- 0,952 and for the NeoSoniX group 1,103 +- 0,741 (P = 0.44) 8 years after surgery. Conclusion. There was minimal PCO difference between these 2 approaches, AquaLase and NeoSoniX. Neither AquaLase nor NeoSoniX technique was able to prevent a natural progression of PCO.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FF - ORL, oftalmologie, stomatologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers

ISSN

1213-8118

e-ISSN

—

Svazek periodika

160

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

143-148

Kód UT WoS článku

000373390800020

EID výsledku v databázi Scopus

2-s2.0-84962339948